Selected article for: "illness median duration and median duration"
Author: Phung, Thuy Thi Bich; Suzuki, Tadaki; Phan, Phuc Huu; Kawachi, Shoji; Furuya, Hiroyuki; Do, Huong Thu; Kageyama, Tsutomu; Ta, Tuan Anh; Dao, Nam Huu; Nunoi, Hiroyuki; Tran, Dien Minh; Le, Hai Thanh; Nakajima, Noriko
Title: Pathogen screening and prognostic factors in children with severe ARDS of pulmonary origin
  • Document date: 2017_7_13
    • ID: 2k2x6jxm_7
    Snippet: Twelve children had a medical history (pneumonia, n = 9; febrile convulsion, n = 1 idiopathic thrombocytopenic purpura, n = 1 and hemosiderosis, n = 1) and two children were positive for human immunodeficiency virus. The median duration from the onset of illness to PICU admission was 9 days, and 21 (37%) patients were admitted to the PICU within 7 days of the onset of illness. The median P/F ratio was 78 mm Hg and 43 (75%) children showed a P/F r.....
    Document: Twelve children had a medical history (pneumonia, n = 9; febrile convulsion, n = 1 idiopathic thrombocytopenic purpura, n = 1 and hemosiderosis, n = 1) and two children were positive for human immunodeficiency virus. The median duration from the onset of illness to PICU admission was 9 days, and 21 (37%) patients were admitted to the PICU within 7 days of the onset of illness. The median P/F ratio was 78 mm Hg and 43 (75%) children showed a P/F ratio of ≤100 mm Hg with a PEEP ≥5 cm H 2 O on the day of PICU admission. All children were intubated and supported on a mechanical ventilator. The Pediatric Risk of Mortality (PRISM) III score was assessed using parameters obtained during the first 12 h of stay in the PICU. 29 PRISM III scores were 0-23 (median 8.0). Glucocorticoid or high-dose intravascular immunoglobulin were administered to 46 (81%) and 36 (63%) children, respectively, as adjunct treatments depending on the physician's decision. Table 2 . Fifty-three (92%) patients were positive for either ADV-B or MeV or CMV. In addition,

    Search related documents:
    Co phrase search for related documents
    • adjunct treatment and human immunodeficiency: 1
    • adjunct treatment and human immunodeficiency virus: 1
    • adjunct treatment and mechanical ventilator: 1
    • adjunct treatment and mechanical ventilator support: 1
    • adjunct treatment and medical history: 1
    • high dose and human immunodeficiency: 1, 2, 3, 4, 5, 6, 7, 8
    • high dose and human immunodeficiency virus: 1, 2, 3, 4, 5, 6, 7, 8
    • high dose and iii score: 1, 2
    • high dose and illness onset: 1, 2
    • high dose and mechanical ventilator: 1, 2, 3
    • high dose and mechanical ventilator support: 1
    • high dose and median duration: 1, 2, 3, 4, 5, 6, 7, 8
    • high dose and medical history: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • high dose and physician decision: 1
    • human immunodeficiency and mechanical ventilator: 1
    • human immunodeficiency and median duration: 1, 2, 3
    • human immunodeficiency and medical history: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • human immunodeficiency and PICU stay: 1
    • human immunodeficiency virus and mechanical ventilator: 1